RhumbLine Advisers
HLVX

RhumbLine Advisers’s HilleVax HLVX Stock Holding History

RhumbLine Advisers’s Portfolio HLVX Stock Details HLVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-44,294
Closed -$64.2K – 4191
2025
Q1 		$64.2K Sell
44,294
-2,234
-5% -$4.13K ﹤0.01% 3516
2024
Q4 		$96.3K Sell
46,528
-2,273
-5% -$4.27K ﹤0.01% 3483
2024
Q3 		$85.9K Buy
48,801
+6,143
+14% +$15.8K ﹤0.01% 3546
2024
Q2 		$617K Buy
42,658
+9,073
+27% +$125K ﹤0.01% 2523
2024
Q1 		$559K Buy
33,585
+1,852
+6% +$29.6K ﹤0.01% 2603
2023
Q4 		$509K Buy
31,733
+4,319
+16% +$57.4K ﹤0.01% 2645
2023
Q3 		$369K Buy
27,414
+838
+3% +$11.8K ﹤0.01% 2803
2023
Q2 		$457K Buy
26,576
+3,570
+16% +$55.3K ﹤0.01% 2744
2023
Q1 		$380K Buy
23,006
+1,228
+6% +$19.6K ﹤0.01% 2536
2022
Q4 		$364K Buy
21,778
+3,624
+20% +$65.4K ﹤0.01% 2601
2022
Q3 		$310K Buy
18,154
+1,056
+6% +$15.4K ﹤0.01% 2714
2022
Q2 		$187K Buy
+17,098
New +$203K ﹤0.01% 2946

Other funds holding HLVX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LMC
Lightspeed Management Company Menlo Park, California $988M AUM 7.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

RhumbLine Advisers's HLVX Position: Q2 2025 in Review

RhumbLine Advisers sold out of HilleVax (HLVX) in Q2 2025, closing a stake of 44,294 shares — an estimated $64.2K sold.

RhumbLine Advisers first reported a position in HLVX in Q2 2022 and held it in 12 quarters. The position peaked at $617K in Q2 2024. 74 funds tracked by Wall St. Rank hold HLVX as of Q2 2025.

  • RhumbLine Advisers reported no remaining HilleVax position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 44,294 HilleVax shares in Q2 2025, an estimated $64.2K.
  • RhumbLine Advisers first reported a position in HilleVax in Q2 2022 and held it in 12 quarters.
  • RhumbLine Advisers's HilleVax position peaked at $617K in Q2 2024.
  • 74 funds tracked by Wall St. Rank held HilleVax as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.